Publications by authors named "C Vener"
Introduction: Breast cancer is the most common cancer among women, and metabolic syndrome (MetS) is a risk factor for breast cancer, especially postmenopausal breast cancer. We evaluated the role of the advanced glycated end products (AGEs) levels contributing to the association between MetS and breast cancer risk.
Methods: Plasma AGEs were measured in a case-control study nested within the Hormones and Diet in the Etiology of Breast Tumors (ORDET) cohort, including 40 incident postmenopausal breast cancer cases (20 with MetS and 20 without) and 40 postmenopausal controls (20 with MetS and 20 without).
Aims/hypothesis: The aim of the present study was to investigate the association between dietary exposures to dioxins, dioxin-like polychlorinated biphenyls (DL-PCBs) and non-dioxin-like polychlorinated biphenyls (NDL-PCBs) and the incidence of type 2 diabetes mellitus (T2DM) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
Methods: This prospective cohort study with a median 11.7 years of follow-up, included 318,416 individuals recruited in 21 centers in eight countries.
Article Synopsis
- A new modeling approach was developed to better estimate the cancer cure fraction (CF) and net survival by considering patients' increased risk of dying from causes other than cancer, rather than assuming equal mortality rates with the general population.
- Data from EUROCARE-6 on head and neck, colorectal, and breast cancer patients aged 40-79 was analyzed, revealing a significant increase in CF, particularly among younger males with head and neck cancer who had a fourfold increased risk of dying from other causes.
- Ignoring the higher mortality risk from non-cancer causes leads to an underestimation of the CF, which is crucial for understanding patient survival and improving their quality of life.
Background: Management of lymphoid malignancies requires substantial health system resources. Total national health expenditure might influence population-based lymphoid malignancy survival. We studied the long-term survival of patients with 12 lymphoid malignancy types and examined whether different levels of national health expenditure might explain differences in lymphoid malignancy prognosis between European countries and regions.
View Article and Find Full Text PDFBackground: We used the comprehensive definition of AYA (age 15 to 39 years) to update 5-year relative survival (RS) estimates for AYAs in Europe and across countries and to evaluate improvements in survival over time.
Methods: We used data from EUROCARE-6. We analysed 700,000 AYAs with cancer diagnosed in 2000-2013 (follow-up to 2014).